Pf Media

The Spring issue of Pf Magazine is out now, with a look at what the future holds for #pharma. Now that digital relationships have been built, how do we make them sustainable? And how do we keep them relevant? bit.ly/3q55bkY

New MHRA Chief Executive Officer appointed - Pf Media bit.ly/3F2F2O6

The impact of EU pharmaceutical reform - Pf Media bit.ly/3KQBWMQ

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media bit.ly/3RcqP4s

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media bit.ly/3Vw2Mjm

Dare to be disruptive – how to model your European go to market strategy for success  - Pf Media bit.ly/3ytkpat

Novartis' leukaemia treatment to be made available on the NHS - Pf Media bit.ly/44qLjvz

NICE recommends new Novartis treatment for brain tumours - Pf Media bit.ly/44hxqQu

Promising new treatment strategy for aggressive form of leukaemia - Pf Media bit.ly/4463eb5

Positive trial results for PharmNovo's pain management drug - Pf Media bit.ly/4ctCIMx

Research uncovers how to target dormant breast cancer cells and prevent relapse - Pf Media bit.ly/3Tyle8T

HCP engagement solutions – being present isn’t enough - Pf Media bit.ly/4cthz4U

Almirall expands pipeline to rare dermatological diseases - Pf Media: bit.ly/48VLPCv

SMC accepts AbbVie’s new Parkinson’s drug within NHS Scotland - Pf Media bit.ly/3TBz8Ix

NICE recommends Janssen’s rare disease treatment - Pf Media bit.ly/49TbGMl

Besins Healthcare appoints new General Manager - Pf Media bit.ly/3SD9T7b

MHRA licenses treatment option for rare autoimmune disease - Pf Media bit.ly/3HPljj8

VPAG survey – have your say - Pf Media bit.ly/3SGTsrC

Kyowa Kirin to acquire Orchard Therapeutics   - Pf Media bit.ly/3PRGWDc

MHRA grants marketing authorisation for LEO’s dermatitis treatment - Pf Media bit.ly/3PuyHg8

First treatment for acute migraine recommended by NICE - Pf Media bit.ly/3PCUFib